Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(22)00266-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Leuk Res
November 2022
Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address:
This phase 2 study describes long-term clinical and immunological effects of fixed-duration ofatumumab (anti-CD20) and alemtuzumab (anti-CD52) combination immunotherapy in 52 patients with previously untreated CLL. The median age was 65 years (range 45-79), 60% had Rai stage 3-4, 40% were IgHV unmutated and 25% had del(17p)/TP53 mutation. Alemtuzumab was given subcutaneously (30 mg tiw, 18 weeks) and ofatumumab intravenously (300-2000 mg) starting week 3 q2 weeks (8 doses).
View Article and Find Full Text PDFTime-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia.
Lancet Oncol
June 2022
Department of Haematology, Hull University Teaching Hospitals NHS Trust, Hull, HU16 5JQ, UK; Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK.
Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Curr Treat Options Oncol
March 2020
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Treatment landscape of chronic lymphocytic leukemia (CLL) has changed since 2014 after the introduction of inhibitors of B-cell receptor signaling pathway (ibrutinib, acalabrutinib, idelalisib and duvelisib) and the inhibitor of the anti-apoptotic protein BCL-2 (venetoclax). In 2019, novel agents were upgraded from being a "great treatment option" to the "preferred choice" for all lines of treatment after number of randomized clinical trials proved their superiority compared to conventional chemoimmunotherapy (CIT) regimens. A growing number of next-generation molecules are in clinical trials with a promise of improved efficacy and less toxicity.
View Article and Find Full Text PDFFrontline Therapy of CLL: Evolving Treatment Paradigm.
Curr Hematol Malig Rep
April 2018
Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 N St. Clair Street, Suite 850, Chicago, IL, 60611, USA.
Purpose Of Review: Chronic lymphocytic leukemia (CLL) has multiple current frontline therapy options, including chemoimmunotherapy (CIT) and most recently, ibrutinib. Here, we review the most recent updates in the frontline treatment of CLL, including updates in CIT, updates in targeted therapies, and ongoing clinical trials.
Recent Findings: Ibrutinib was FDA-approved for the upfront treatment of CLL in 2016 after being studied in older patients and those with 17p deletions or TP53 mutations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!